MIVI Neuroscience Announces First Patient Enrolled in EVAQ Clinical Study for Ischemic Stroke Treatment

EDEN PRAIRIE, Minn., Dec. 1, 2020 /PRNewswire/ -- MIVI Neuroscience, Inc. announced that it has enrolled the first patient in the Food and Drug Administration approved Investigational Device Exemption EVAQ Clinical Study. The procedure took place at Hôpital de Purpan in Toulouse, France....

from PR Newswire: https://ift.tt/37s1XOA